Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 2/20 | 0.56 |
| ▸ | NOS3 known ✓ | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 known ✓ | P29475 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
| ▸ | NRP1 | O14786 | 2/20 | 0.50 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30391184 | 0.96 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL29356389 | 0.96 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL28409679 | 0.96 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL29603738 | 0.96 | CYP1A2 (0.61) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| Hydrochloric Acid SCHEMBL1880117 | 0.93 | CYP1A2 (0.58) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL27898034 | 0.93 | CYP2C19 (0.65) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL1735525 | 0.93 | CYP2C19 (0.65) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL29351011 | 0.89 | CYP1A2 (0.56) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL1736266 | 0.88 | NPY1R (0.55) | NPY1RNPY2RNPY4RCYP2C19NOS2 | |
| SCHEMBL29566514 | 0.87 | NPY1R (0.52) | NPY1RNPY2RNPY4RCYP2C19NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116769738-B | Glutamyl cysteine synthetase mutant and application thereof in glutathione synthesis | 江苏集萃工业生物技术研究所有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12569488-B2 | Methods for predicting response to arginine deprivation therapy based on plasma arginine levels in cancer patients | POLARIS PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4673533-A1 | METHODS OF TREATING CANCERS | Polaris Pharmaceuticals Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| CN-120137930-A | Transaminase mutant applied to N-Boc-3-aminopiperidine synthesis | 浙江工业大学 | 2025-06-13 | — | — | CN | claimed |
| CN-116144622-B | Cyclodextrin glucosyltransferase with improved solvent tolerance and preparation thereof | 江南大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120060225-A | Tryptophan synthase mutant for synthesizing cysteine or cystine, derivative thereof, synthesis method and application | 苏州华赛生物工程技术有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120041410-A | Thermostable conjugated polyketide reductase mutant and application thereof in catalytic synthesis of D-pantolactone | 浙江工业大学 | 2025-05-27 | — | — | CN | claimed |
| CN-119932004-A | D-ribose-5-phosphate isomerase mutant and application thereof | 齐鲁工业大学(山东省科学院) | 2025-05-06 | — | — | CN | claimed |
| CN-119799674-A | ALS inhibitor broad-spectrum resistance mutant protein and application thereof | 海南乾鸿本源生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119752826-A | 4-Hydroxyphenylacetic acid 3-hydroxylase mutant and application thereof | 天津大学 | 2025-04-04 | — | — | CN | claimed |
| CN-114686451-A | Amine dehydrogenase mutant and application thereof in preparation of (S) -5-methyl-2-pyrrolidone | 华东理工大学 | 2022-07-01 | — | — | CN | claimed |
| CN-114645007-A | Recombinant strain, engineering bacterium for high yield of 2' -fucosyllactose based on recombinant strain and application of engineering bacterium | 南通励成生物工程有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-111499718-B | Human alpha interferon receptor binding related site mutant and application thereof | 复旦大学 | 2022-06-14 | — | — | CN | claimed |
| CN-111909907-B | Aspartate oxidase mutant, engineering bacteria and application of aspartate oxidase mutant in preparation of refined glufosinate-ammonium through oxidation-reduction coupling | 浙江工业大学 | 2022-05-24 | — | — | CN | claimed |
| CN-114181288-B | Process for producing L-valine, gene used therefor and protein encoded by the gene | 北京中科伊品生物科技有限公司 | 2022-05-03 | — | — | CN | claimed |
| CN-114426959-A | Phosphorylcholine cytidine acyl transferase mutant and application thereof | 郑州大学 | 2022-05-03 | — | — | CN | claimed |
| CN-111621482-B | Glufosinate-ammonium dehydrogenase mutant, gene engineering bacteria and one-pot multi-enzyme synchronous directed evolution method | 浙江工业大学 | 2022-04-29 | — | — | CN | claimed |
| CN-114366813-A | Target for treating tumor, application of target and tumor treatment preparation | 中南大学 | 2022-04-19 | — | — | CN | claimed |
| CN-111424027-B | Site-directed mutagenesis modified alginate lyase mutant and application thereof | 江南大学 | 2022-03-01 | — | — | CN | claimed |
| CN-111996178-B | Histone alcohol phosphate aminotransferase mutant, engineering bacterium and application | 山东阳成生物科技有限公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569488-B2 | Methods for predicting response to arginine deprivation therapy based on plasma arginine levels in cancer patients | ARG1, PADI3, PADI4 | NOS2 519/4885NOS3 329/4885NOS1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.